Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

ARYx Therapeutics Announces Results Of Phase 2/3 Clinical Trial On Anticoagulant Agent Tecarfarin
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced results from its Phase 2/3 clinical trial, EmbraceAC, comparing its novel anticoagulant agent tecarfarin (previously ATI-5923) with the leading oral anticoagulant warfarin. In this trial, tecarfarin demonstrated efficacy essentially the same as in earlier Phase 2 studies but did not achieve the primary endpoint of superiority over warfarin, as measured by time in therapeutic range (TTR). This was due to the virtually unprecedented performance of warfarin in this trial. Using the International Normalized Ratio (INR), which is the standard measure of anticoagulation to evaluate TTR, the patients in the trial who were administered tecarfarin stayed within the target therapeutic range 74.0% of the time treated as compared to those patients receiving warfarin who stayed within the target therapeutic range 73.2% of the time (p=0.506). The result for the warfarin group was unexpected based upon the extensive history of prior studies and published literature for the drug. Tecarfarin appeared to be well tolerated by the patients in this Phase 2/3 clinical trial.
generic viagra online
Women More Susceptible To Harmful Effects Of Smoking
Women may be more susceptible to the lung damaging effects of smoking than men, according to new research by Inga-Cecilie Soerheim, M.D., and her colleagues from Channing Laboratory, Brigham and Women"s Hospital and University of Bergen, Norway.
News of the day
Technology On Way To Forecasting Humanity's Needs
Much as meteorologists predict the path and intensity of hurricanes, Indiana University"s Alessandro Vespignani believes we will one day predict with unprecedented foresight, specificity and scale such things as the economic and social effects of billions of new Internet users in China and India, or the exact location and number of airline flights to cancel around the world in order to halt the spread of a pandemic.
Public Health

Agios Pharmaceuticals' Focus Of Drug Research - Cancer Metabolism - Selected For Stand Up To Cancer Grant

Agios Pharmaceuticals today announced that Stand Up To Cancer (SU2C), a charitable initiative for new cancer treatments, has selected the Cancer Metabolism "dream team" led by Agios founder Dr. Craig Thompson and including Agios advisors Drs. Chi Dang and Joshua Rabinowitz. Cancer Metabolism is one of only five research areas chosen to share in $73.6 million in translational research funding, based on a rigorous selection process by independent scientific advisors assembled by SU2C"s scientific partner, the American Association for Cancer Research (AACR). Cancer metabolism is a new and exciting field of biology that represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth. This new understanding of a fundamental mechanism of cancer represents a powerful Achilles" heel to target this deadly disease. With the help of Craig Thompson, MD, Chi Dang, MD, and other key advisors including Lewis Cantley, PhD, and Tak Mak, PhD, Agios was founded a year ago to lead the translation of cancer metabolism biology and decades of metabolic biochemistry into novel cancer therapeutics that will make a difference for patients. In its first year of operation, Agios has taken a leadership position in the field of Cancer Metabolism with more than 40 employees and a rapidly emerging drug pipeline. Yesterday, Agios announced the appointment of its new leadership team to further lead and grow the vision of Agios. David Schenkein, MD, of Genentech will assume his role as Chief Executive Officer in August and Duncan Higgons, formerly of Archemix, became the Chief Operating Officer in May. "It is great to see Stand Up To Cancer and AACR recognize and further validate the therapeutic potential of Cancer Metabolism which has been the driving vision behind building Agios over the past year," said David Schenkein, incoming Chief Executive Officer of Agios Pharmaceuticals. "The progress to date of Agios has been impressive, bringing together great people, a passionate culture, deep science and an emerging pipeline of novel drugs that is leading the field rapidly downstream towards the clinic." Stand Up To Cancer worked in collaboration with the American Association for Cancer Research (AACR) to identify and fund "dream teams" in areas of cancer research that provide the most promising near term potential breakthrough therapies for patients. Cancer Metabolism was selected as one of the five research areas to receive SU2C research grants, based on the recommendation of a scientific advisory committee assembled by AACR. The Cancer Metabolism dream team includes four elite scientists, three of whom are key Agios founders and advisors: - Co-Leader - Agios Co-Founder Craig B. Thompson, M.D., Director, Abramson Cancer Center, University of Pennsylvania. - Principal Reseacher - Agios Advisor Chi Van Dang, M.D., Ph.D., Vice Dean for Research of Johns Hopkins University School of Medicine. - Principal Researcher - Agios Advisor Joshua D. Rabinowitz, M.D., Ph.D., Assistant Professor of Chemistry and Integrated Genomics, Princeton University. Agios Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009